Literature DB >> 6937236

Laser flow cytometric studies on the intracellular fluorescence of anthracyclines.

A Krishan, R Ganapathi.   

Abstract

We have used a laser flow cytometer to excite and quantitate the intracellular fluorescence of cells exposed in vitro and in vivo to various anthracyclines. In cells exposed to Adriamycin (ADR), intracellular drug fluorescence appeared slowly and reached a peak after 4 hr of incubation. Cells incubated with 10 micrograms/ml were 5 times more fluorescent than were cells incubated with 1 microgram/ml. Cells exposed to daunomycin were 2 to 4 times more fluorescent than were cells similarly exposed to ADR, and the intracellular appearance of daunomycin fluorescence was much more rapid. Cells exposed to N-trifluoroacetyladriamycin and carminomycin had higher amounts of intracellular fluorescence (2 to 4 times), and peak values were reached much more rapidly than in cells exposed to ADR. In cells exposed to rubidazone, fluorescence increased 2- to 4-fold with increased drug concentration and length of exposure. In contrast, nogalamycin fluorescence reached a peak after 60 min of incubation, and a 10-fold increase in drug concentration increased fluorescence only 2-fold. In animals given injections of ADR (4 mg/kg) and sacrificed after 3 hr, drug fluorescence could be detected in tumor and spleen cells. In contrast, fluorescence in heart nuclei was barely recognizable. However, incubation of isolated nuclei in ADR (1 microgram/ml) showed that bone marrow and heart nuclei had greater amounts of ADR fluorescence (2- to 3-fold) than did spleen or liver nuclei similarly treated. The use of laser flow cytometry for monitoring intracellular anthracycline transport, binding, and efflux is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6937236

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.

Authors:  A W El-Kareh; T W Secomb
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

2.  Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.

Authors:  N Baldini; K Scotlandi; M Serra; K Kusuzaki; T Shikita; M C Manara; D Maurici; M Campanacci
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Optimized fluorescent probe combinations for evaluation of proliferation and necrosis in anthracycline-treated leukaemic cell lines.

Authors:  J Boutonnat; M Barbier; K Muirhead; M Mousseau; X Ronot; D Seigneurin
Journal:  Cell Prolif       Date:  1999-08       Impact factor: 6.831

4.  Potential limitations of in vitro clonogenic drug sensitivity assays.

Authors:  G W Dong; H D Preisler; R Priore
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Laser flow cytometric studies on the intracellular accumulation of anthracyclines when combined with heat.

Authors:  Y Sakaguchi; Y Maehara; S Inutsuka; I Takahashi; M Yoshida; Y Emi; H Baba; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

7.  Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.

Authors:  K S Sridhar; A Krishan; T S Samy; A Sauerteig; L L Wellham; G McPhee; R C Duncan; S Y Anac; B Ardalan; P W Benedetto
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Uptake of adriamycin by human leukemic cells as measured by flow cytometry.

Authors:  H D Preisler; A Raza
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

9.  Continuous in situ electrochemical monitoring of doxorubicin efflux from sensitive and drug-resistant cancer cells.

Authors:  C Yi; M Gratzl
Journal:  Biophys J       Date:  1998-11       Impact factor: 4.033

10.  Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.

Authors:  M E Fox; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.